Medicare Enrolled
Dr. Masha Resman, M.D.
Hospitalist Physician · Sugar Land, TX
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Resman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Resman?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Resman
Dr. Masha Resman is a hospitalist physician in Sugar Land, TX, with 17 years of NPI registration. Based on federal Medicare data, Dr. Resman performed 3,163 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Resman received a total of $7,763 from 34 pharmaceutical and/or device companies across 310 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Resman is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years of NPI registration
▲ Top 5% volume in TX
$7,763 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗3,163
Medicare services
Top 5% in TX for hospitalist physician
Not available
Unique patients (not deduplicated)
$29
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 1,260 | $19 | $70 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
392 | $87 | $157 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
267 | $8 | $11 |
| Hemoglobin A1c test (diabetes monitoring) A blood test that measures your average blood sugar levels over the past two to three months. |
163 | $10 | $38 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
154 | $10 | $50 |
| Thyroid stimulating hormone (TSH) test A blood test that measures the level of thyroid stimulating hormone to evaluate thyroid function. |
125 | $16 | $47 |
| Free thyroxine (T4) test A blood test that measures the level of free thyroxine, a thyroid hormone, in the bloodstream. |
121 | $9 | $25 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
115 | $62 | $111 |
| Lipid panel (cholesterol and triglycerides) A blood test that measures cholesterol and triglyceride levels. |
106 | $13 | $50 |
| Urine microalbumin test (kidney screening) A laboratory test that measures the amount of microalbumin, a small protein, in a urine sample. This test is used to detect early signs of kidney damage. |
97 | $6 | $21 |
| Creatinine test (kidney function) A blood test that measures the amount of creatinine to assess kidney function or detect muscle injury. |
87 | $5 | $21 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
79 | $10 | $70 |
| Ultrasound of head and neck soft tissue This procedure uses sound waves to create images of the soft tissues in the head and neck area. It allows for the visualization of structures beneath the skin without using radiation. |
42 | $75 | $360 |
| Vitamin D level test A blood test to measure the amount of Vitamin D-3 in your body. |
41 | $29 | $125 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
38 | $118 | $240 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
28 | $77 | $157 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
22 | $123 | $208 |
| Bone density scan (DEXA) of hip, pelvis, and spine This test measures bone density in the hip, pelvis, and spine to assess bone strength. It also includes an assessment for spine fractures. |
15 | $49 | $300 |
| Free T3 thyroid hormone test A blood test that measures the level of free triiodothyronine (T3) hormone in your body. This helps assess how well your thyroid gland is functioning. |
11 | $17 | $45 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
Industry Payment Transparency
Open Payments through 2024 ↗$7,763
Total received (2018-2024)
Avg $1,109/year across 7 years
Top 4% in TX for hospitalist physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
34
Companies
310
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,246
2023
$1,053
2022
$1,325
2021
$1,022
2020
$573
2019
$455
2018
$90
Payments by company (2024)
Corcept Therapeutics
$2,215
Lilly USA, LLC
$169
Radius Health, Inc.
$157
Novo Nordisk Inc
$148
Amgen Inc.
$90
ABBVIE INC.
$84
Xeris Pharmaceuticals, Inc.
$76
Tandem Diabetes Care, Inc.
$59
Medtronic, Inc.
$50
Dexcom, Inc.
$48
Abbott Laboratories
$38
IBSA Pharma Inc.
$37
Bayer Healthcare Pharmaceuticals Inc.
$31
Boehringer Ingelheim Pharmaceuticals, Inc.
$23
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$20
Top 3 companies account for 78.3% of 2024 payments
All-time payments by company (2018-2024) ›
Corcept Therapeutics
$2,347
Amgen Inc.
$525
Novo Nordisk Inc
$507
Horizon Therapeutics plc
$451
Abbott Laboratories
$427
Lilly USA, LLC
$425
ABBVIE INC.
$366
Radius Health, Inc.
$353
SANOFI-AVENTIS U.S. LLC
$309
Dexcom, Inc.
$285
Tandem Diabetes Care, Inc.
$199
IBSA Pharma Inc.
$181
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$149
Xeris Pharmaceuticals, Inc.
$143
Merck Sharp & Dohme LLC
$137
AstraZeneca Pharmaceuticals LP
$130
Merck Sharp & Dohme Corporation
$130
AbbVie Inc.
$104
Amneal Pharmaceuticals LLC
$84
Bayer HealthCare Pharmaceuticals Inc.
$70
Boehringer Ingelheim Pharmaceuticals, Inc.
$58
Insulet Corporation
$51
Medtronic, Inc.
$50
Bayer Healthcare Pharmaceuticals Inc.
$50
DEXCOM, INC.
$48
Alvogen Inc
$44
Amryt Pharma Holdings Ltd
$22
Supernus Pharmaceuticals, Inc.
$21
Amarin Pharma Inc.
$19
Ironwood Pharmaceuticals, Inc
$18
CeQur Corporation
$17
Medtronic MiniMed, Inc.
$17
Companion Medical, Inc.
$14
Currax Pharmaceuticals LLC
$13
Top 3 companies account for 43.5% of all-time payments
Associated products mentioned in payments ›
BAQSIMI · BELSOMRA · CONTRAVE · CREON · CYCLOSET · CeQur Simplicity · DEXCOM CGM · DEXCOM G6 CGM SYSTEM · DEXCOM G6 TRANSMITTER · Dexcom G6 Transmitter · EVENITY · FARXIGA · FREESTYLE LIBRE · FreeStyle Libre · FreeStyle Libre blood glucose Flash Monitoring System · GVOKE HYPOPEN · GVOKE PFS · HUMULIN · InPen · JANUMET · JANUVIA · JARDIANCE · KEVEYIS · KRYSTEXXA · Kerendia · Korlym · LINZESS · Linzess · MINIMED 780G · MOUNJARO · MYCAPSSA · Minimed 670G System · Omnipod · Ozempic · Prolia · RAYOS · RYBELSUS · Repatha · Rybelsus · SOLIQUA 100/33 · STEGLATRO · STEGLUJAN · SYNTHROID · TEPEZZA · TERIPARATIDE · TOUJEO · TRADJENTA · TRULICITY · Tirosint · Tymlos · UBRELVY · UNITHROID · VIBERZI · Vascepa · XYOSTED · ZEPBOUND · t-slim insulin pump · t:slim X2 Insulin Pump with Control-IQ · t:slim X2 insulin pump
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hospitalist physicians in nearby ZIP areas
193
County median income
$113,409
Nearest hospital to ZIP centroid (approximate)
ST LUKE'S SUGAR LAND HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Resman is a clinical cardiology specialist, with above-average Medicare volume (top 5% in TX), with 17 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Resman experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Resman performed 1,260 denosumab injection (prolia/xgeva) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Resman receive payments from pharmaceutical companies?
Yes. Dr. Resman received a total of $7,763 from 34 companies across 310 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Resman's costs compare to other hospitalist physicians in Sugar Land?
Dr. Resman's average Medicare payment per service is $29. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Resman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hospitalist Physicians in Sugar Land
Browse hospitalist physicians in Sugar Land ranked by procedure volume and transparency data.
Highest volume
Top Hospitalist Physicians in TX
Hospitalist physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hospitalist Physicians in TX
Which TX hospitalist physicians receive the most from drug and device companies.
By company
Corcept Therapeutics Payments to Doctors
See all physicians who received payments from Corcept Therapeutics.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Novo Nordisk Inc Payments to Doctors
See all physicians who received payments from Novo Nordisk Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology